WAYNE, Pa., Nov. 3 /PRNewswire-FirstCall/ -- Escalon Medical Corp.
(Nasdaq: ESMC) today announced that it has been named to Forbes' "200 Best
Small Companies," which appears in the November 1 issue of the magazine.  This
is the first year for Escalon's inclusion and the Company was ranked 75th.
    To make the Forbes' 2004 list, a company must "show a consistent pattern
of positive growth during a five-year period, as well as over the last
12 months."  Forbes selected companies with sales in the $5 million to
$750 million range, net profit margins greater that 5% and share prices above
$5 as of October 1, 2004.  Looking at individual category ratings, Escalon
ranked 65th in return on equity, 81st on sales growth and 62nd in earnings per
share growth.
    Escalon Medical Corp.'s CEO, Richard J. DePiano commented, "We are pleased
to have been included in the Forbes "200 Best" list.  The strategic
repositioning of the Company over the last several years has allowed us to
report solid revenue and earnings gains and enabled us to significantly
improve our balance sheet.  Our Sonomed and vascular access businesses have
been key to our transformation and our recent acquisition of Drew Scientific
is expected to provide another growth vehicle for the future."

    Founded in 1987, Escalon develops, markets and distributes ophthalmic
diagnostic, surgical and pharmaceutical products as well as vascular access
devices.  Drew Scientific, which operates as a separate division, provides
instrumentation and consumables for the diagnosis and monitoring of medical
disorders in the areas of diabetes, cardiovascular diseases and hematology, as
well as veterinary hematology and blood chemistry.  The Company seeks to
utilize strategic partnerships to help finance its development programs and is
also seeking acquisitions to further diversify its product line to achieve
critical mass in sales and take better advantage of the Company's distribution
capabilities.  Escalon has headquarters in Wayne, Pennsylvania and
manufacturing operations in Long Island, New York, New Berlin, Wisconsin,
Dallas, Texas, Oxford, Connecticut and Barrow Furness, U.K.

     Note:  This press release contains statements that are considered
forward-looking under the Private Securities Litigation Reform Act of 1995,
including statements about the Company's future prospects.  They are based on
the Company's current expectations and are subject to a number of
uncertainties and risks, and actual results may differ materially.  The
uncertainties and risks include whether the Company is able to improve upon
the operations of the Company's business units, generate cash and identify,
finance and enter into business relationships and acquisitions, including the
exchange offer of Drew Scientific, uncertainties and risks related to new
product development, commercialization, manufacturing and market acceptance of
new products, marketing acceptance of existing products in new markets, the
continuity of royalty revenue, research and development activities, including
failure to demonstrate clinical efficacy, delays by regulatory authorities,
scientific and technical advances by the Company or third parties,
introduction of competitive products, third party reimbursement and physician
training as well as general economic conditions.  Further information about
these and other relevant risks and uncertainties may be found in the Company's
report on Form 10-K, and its other filings with the Securities and Exchange
Commission, all of which are available from the Commission as well as other
sources.

Link to this page: